Taysha Gene Therapies (TSHA) PT Raised to $13 at Goldman Sachs

July 21, 2026 6:38 AM

Goldman Sachs analyst Salveen Richter raised the price target on Taysha Gene Therapies (NASDAQ: TSHA) to $13.00 (from $11.00) while maintaining a Buy rating.

No results found